share_log

美股异动 | Candel Therapeutics(CADL.US)涨近18%,瑞银及杰富瑞给予该股“买入”评级

Us stocks move | Candel Therapeutics (CADL.US) rises nearly 18%, UBS and Jefferies give the stock a "buy" rating

智通財經網 ·  Aug 23, 2021 23:40

Candel Therapeutics (CADL.US), a biopharmaceutical company, rose nearly 18 per cent to $7.43 as of 23:39 Beijing time on Monday, Aug. 23. Credit Suisse gave the stock an "outperform" rating of $15, UBS a "buy" rating of $9 and Jeffery, an investment bank, with a "buy" rating of $22.

Founded in 2003, Candel Therapeutics is a phase III clinical biotechnology company that develops cancer immunotherapy aimed at improving the lives of cancer patients and their families.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment